FindTrial
Sign In

Stem cell therapy in COVID-19

Investigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19: a pilot study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200418047121N2
Enrollment
6
Registered
2020-05-05
Start date
2020-05-09
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Three Patients suffering from COVID-19 with acute respiratory infections and severe lung involvement will be allocated to this group under the supervision of the me

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with COVID19 Acute respiratory infectious symptoms and severe lung involvement

Exclusion criteria

Exclusion criteria: Patients with mild symptoms and mild lung involvement

Design outcomes

Primary

MeasureTime frame
Biomarker expression. Timepoint: two weeks after last cell therapy. Method of measurement: Flowcytometery.;IL-6 and IL-1 Level. Timepoint: Before Cell injection and two weeks after cell injection. Method of measurement: Elisa Kit.;Respiratory and lung function. Timepoint: Before Cell injection and two weeks after cell injection. Method of measurement: Physical examination , O2 saturation and CT Scan.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKamran Mansouri

Kermanshah University of Medical Sciences

kamranmansouri@gmail.com+98 83 3427 6473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026